Key Drivers
- Strong Liquidity
- Persistent Losses
- Weak Cash Flow
AIAI Summary
HTFL now looks like a show-me commercialization story: strong revenue acceleration, raised guidance, and 80%+ gross margins validate product traction, but with persistent operating losses/free cash burn and a rich ~12.4x sales multiple, investors need to see Plaque Analysis adoption compound fast enough to justify the valuation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Persistent Losses
- •Weak Cash Flow
HTFL has a strong liquidity and low-debt balance sheet, but persistent operating losses, negative free cash flow, and a rich sales/book-based valuation make the stock look risky despite solid gross margins.
Price Behavior
Key Price Behavior Insights:
- •Support failure
- •Sharp reversal
- •Near oversold
HTFL turned slightly down over the last month after a sharp 5/15 selloff from $32.24 to $28.32 broke $28.5-$29.0 support, leaving it vulnerable to a test of $27.4-$27.0 unless it quickly reclaims $29.5-$30.0.
Sharp drop from $32.24 to $28.32 on 2026-05-15 signaled a sudden loss of momentum
Sentiment & News
Key News Insights:
- •Revenue surge
- •Plaque adoption
- •IPO attention
HeartFlow's Q1 update pointed to faster revenue growth, broader AI-tool adoption, and a higher 2026 outlook, signaling improving execution and rising investor attention.
Positive for the instrument, as stronger demand and a raised outlook suggest continued upside, though insider selling could slightly cap sentiment
Similar Companies in Healthcare
Other companies in the same sector with AI ratings